MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, FHTX had $26,964K increase in cash & cash equivalents over the period. -$86,149K in free cash flow.

Cash Flow Overview

Change in Cash
$26,964K
Free Cash flow
-$86,149K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Impairment of long-lived assets
    • Noncash lease expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Deferred revenue
    • Others

Cash Flow
2025-12-31
Net loss
-74,283
Stock-based compensation expense
10,399
Depreciation and amortization expense
3,332
Loss on disposal of property and equipment
-31
Gain on lease modification
1,632
Impairment of long-lived assets
5,914
Noncash lease expense
4,206
Accretion of discount on marketable securities
1,926
Prepaid expenses and other current assets
-2,827
Accounts payable
481
Accrued expenses and other liabilities
2,204
Operating lease liabilities
-6,743
Deferred revenue
-30,909
Net cash used in operating activities
-86,099
Purchases of property and equipment
50
Purchases of marketable securities
131,247
Proceeds from maturities of marketable securities
243,337
Net cash provided by (used in) investing activities
112,040
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-Prefunded Warrants
0
Payments of public offering costs
0
Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan
483
Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions-At Market Offering
540
Net cash provided by financing activities
1,023
Net increase (decrease) in cash, cash equivalents and restricted cash
26,964
Cash, cash equivalents and restricted cash at beginning of period
57,162
Cash, cash equivalents and restricted cash at end of period
84,126
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$243,337K Proceeds from offeringsof common stock and...$540K Proceeds from issuance ofcommon stock upon...$483K Net cash provided by(used in) investing...$112,040K Net cash provided byfinancing activities$1,023K Canceled cashflow$131,297K Net increase(decrease) in cash, cash...$26,964K Canceled cashflow$86,099K Purchases of marketablesecurities$131,247K Purchases of property andequipment$50K Stock-based compensationexpense$10,399K Impairment of long-livedassets$5,914K Noncash lease expense$4,206K Depreciation andamortization expense$3,332K Prepaid expenses andother current assets-$2,827K Accrued expenses andother liabilities$2,204K Accounts payable$481K Loss on disposal ofproperty and equipment-$31K Net cash used inoperating activities-$86,099K Canceled cashflow$29,394K Net loss-$74,283K Deferred revenue-$30,909K Operating leaseliabilities-$6,743K Accretion of discount onmarketable securities$1,926K Gain on leasemodification$1,632K

Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics Inc. (FHTX)